



Taylor & Francis Group
an informa business

CHOOSE **open**

EXPERT MEDICAL RESEARCH

FROM TAYLOR & FRANCIS

Explore the Expert Review, Expert Opinion, Expert Research, and Expert Medicine series



Introducing the

EXPERT COLLECTION

INCLUDES
ORIGINAL
RESEARCH

The Expert Collection published by Taylor & Francis is the world's largest series of review journals in Research & Development and clinical medicine.

The Expert Collection is comprised of 27 peer-reviewed journals combining the well-established Expert Opinion and Expert Review series into one essential and comprehensive collection.

What makes the Expert Collection different?

The Expert Collection combines first-class literature reviews with the personal opinions of our expert authors who are all internationally recognized experts in their fields. They provide their insights about where research is now, where it should go next and how it should get there. Reviews published in the Expert Collection always end with an expert opinion.

The Expert Collection publishes:

- Reviews
- Editorials
- Original research
- Drug evaluations
- Treatment evaluations
- Clinical trial evaluations
- Technology evaluations
- Patent evaluations
- Key paper evaluations
- Patient Perspectives
- Special reports
- Systematic Reviews
- Letters to Editor
- Video abstracts
- Podcast articles
- Plain Language Summary of Publications

“ In my opinion, the Expert Collection is the most relevant journal review series in the area of Pharmacology. The Expert Collection is a credible, topical, and scholarly resource that I have come to rely on in my role as a leader of international pharmacological studies. It is apparent that the peer review process is thorough and critical, and the editorial process is unparalleled in terms of author support. ”

Dr Roger McIntyre, *University of Toronto*, Editor-in-Chief
Expert Opinion on Drug Safety

The Expert Opinion journals cover the R&D pipeline across 10 journals



DRUG DISCOVERY PRECLINICAL PHASE I PHASE II PHASE III LAUNCH

The Expert Review journals cover 17 different areas of clinical medicine

- Anticancer Therapy
- Anti-infective Therapy
- Cardiovascular Therapy
- Clinical Immunology
- Clinical Pharmacology
- Endocrinology & Metabolism
- Gastroenterology & Hepatology
- Hematology
- Medical Devices
- Molecular Diagnostics
- Neurotherapeutics
- Ophthalmology
- Pharmacoeconomics & Outcomes Research
- Proteomics
- Precision Medicine & Drug Development
- Respiratory Medicine
- Vaccines

The Expert Review Series

						
Journal	Expert Review of Anticancer Therapy	Expert Review of Anti-infective Therapy	Expert Review of Cardiovascular Therapy	Expert Review of Clinical Immunology	Expert Review of Clinical Pharmacology	Expert Review of Endocrinology & Metabolism
Impact Factor Scope	2.9 Appraisal and commentary on the major trends in cancer care and highlights on the performance of new therapeutic and diagnostic approaches.	4.2 Therapeutics and diagnostics in the treatment of infectious disease.	1.8 Evaluation of new diagnostic and therapeutic cardiovascular modalities.	3.9 Performance of new therapeutic and diagnostic modalities in clinical immunology.	3.6 Critical analysis of safety, tolerability, efficacy and therapeutic applications of new therapies.	2.7 Extensive coverage of research and clinical advancements in the field of endocrine control, metabolism and novel therapeutics.
Medline indexed?	Yes	Yes	Yes	Yes	Yes	Yes
						
Journal	Expert Review of Gastroenterology & Hepatology	Expert Review of Hematology	Expert Review of Medical Devices	Expert Review of Molecular Diagnostics	Expert Review of Neurotherapeutics	Expert Review of Ophthalmology
Impact Factor Scope	3.8 Latest advances in pathological, biochemical and physiological understanding of diseases affecting the gastrointestinal tract and liver.	2.3 Commentary and analysis to elucidate best clinical practice in hematology.	2.9 Commentary, analysis, and debate on the development, testing, and clinical use of devices.	3.9 Latest advances in the field of molecular diagnostics including the detection and monitoring of the molecular causes of disease.	3.4 Analysis of drugs and medicines in clinical neurology and neuropsychiatry.	0.9 Commentary and debate on current and emerging approaches in ocular medicine.
Medline indexed?	Yes	Yes	Yes	Yes	Yes	–
						
Journal	Expert Review of Pharmacoeconomics & Outcomes Research	Expert Review of Proteomics	Expert Review of Precision Medicine & Drug Development	Expert Review of Respiratory Medicine	Expert Review of Vaccines	
Impact Factor Scope	1.8 Cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches.	3.8 Technologies, methods, and discoveries from the field of proteomics.	1.0 Original research and review articles covering the development and clinical application of medicine to be used in a personalized therapy setting.	2.9 Commentary from international leaders in the fields of obstructive, restrictive, vascular, and infectious respiratory diseases.	5.5 Analysis of the clinical effectiveness of new vaccines plus new developments in vaccine technology.	
Medline indexed?	Yes	Yes	–	Yes	Yes	

The Expert Opinion Series

DRUG DISCOVERY

PRECLINICAL

PHASE I



Journal	Expert Opinion on Therapeutic Patents	Expert Opinion on Drug Discovery	Expert Opinion on Therapeutic Targets	Expert Opinion on Investigational Drugs	Expert Opinion on Biological Therapy
Impact Factor	5.4	6.0	4.6	4.9	3.6
Scope	Technological advances and developments in pharmaceutical patents, with a strong medicinal chemistry focus.	Novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates.	Novel molecular drug targets and their potential for drug discovery/disease treatment.	Drugs and drug classes in early phase I/II clinical development.	Discovery, development, and clinical application of vaccines, antibodies, stem cells, genetic therapies, and hormone or protein-based therapies.
Medline indexed?	Yes	Yes	Yes	Yes	Yes

PHASE II

PHASE III

LAUNCH



Journal	Expert Opinion on Drug Delivery	Expert Opinion on Drug Metabolism & Toxicology	Expert Opinion on Emerging Drugs	Expert Opinion on Pharmacotherapy	Expert Opinion on Drug Safety
Impact Factor	5.0	3.9	2.7	2.5	3.0
Scope	Drug delivery technologies and new drug formulations.	Approaches to the ADME-Tox arena, as well as metabolic, pharmacokinetic, and toxicological issues relating to specific drugs or drug classes.	Focus on drugs coming up through the pipeline, analysis on what the next drugs to come on to the market are likely to be and their impact on disease management.	Newly approved or near to launch drugs and drug classes.	Post-marketing and pharmacovigilance studies as well as the safety and adverse event profiles of marketed drugs.
Medline indexed?	Yes	Yes	Yes	Yes	Yes

Introducing

EXPERT MEDICINE

NEW

27 CUTTING-EDGE
JOURNALS NEW TO
TAYLOR & FRANCIS


The Expert Medicine journals are a natural complement to the Expert Opinion and Expert Review series, deepening the breadth and depth of subject coverage. Internationally recognized, expert authors provide critical insights into the latest research, where the research should go next and how it should get there. 17 journals publish under a hybrid model and now form the Expert Medicine library collection. 10 journals are published fully Open Access.

- *Bioanalysis* is a must have for anyone working on techniques and methods used for the detection or quantitative study of analytes in human or animal biological samples.
- Expert Medicine's *Future Medicinal Chemistry* complements Expert Opinion's *Expert Opinion in Therapeutic Patents* and provides research articles and broader coverage of the area.
- Expert Medicine's journals *Nanomedicine* and *Therapeutic Delivery* sit as a sister titles to *Expert Opinion on Drug Delivery* providing comprehensive coverage of drug delivery and nanomedicine from bench to bedside.
- Expert Medicine journals add more flagship 'omics titles to the T&F portfolio, these journals publish cutting edge research and opinion in areas that are rapidly progressing and becoming increasingly important to clinical medicine.




Get in touch...

If you would like to add Expert Medicine to your collection, or you are an existing subscriber for these journals and would like to speak to someone, please email expertmedicine@taylorandfrancis.com


Expert Medicine Series



Journal	Biomarkers in Medicine	Epigenomics	Future Cardiology	Future Microbiology	Future Oncology	Future Virology
Impact Factor	1.9	3.0	1.6	2.5	3.0	2.1
Scope	Advances understanding in the potential and actual applications of Biomarkers research, translating knowledge into the clinic.	A critical overview of the latest and most significant advances as they unfold and explores their potential application in the clinical setting.	Highlights the new molecular approach to advancing cardiovascular therapy.	Covers basic, translational and clinical research in microbiology (bacteriology, virology, mycology and parasitology)	A MEDLINE-indexed journal that offers insights into cancer treatments, personalized strategies, and their clinical implications.	Covers a wide range of topics, from new or re-emerging outbreaks to viral vectors, and looks at the impact on human health.
Medline indexed?	Yes	Yes	Yes	Yes	Yes	Yes



Journal	Immunotherapy	Nanomedicine	Neurodegenerative Disease Management	Pain Management	Personalized Medicine	Pharmacogenomics
Impact Factor	2.7	4.7	2.3	1.4	1.7	1.9
Scope	Offers the scientific community an interdisciplinary forum, providing information on the most recent advances of various aspects of immunotherapies.	A uniquely medicine-focused journal, addressing the important challenges and advances in nanomedicine.	Comprehensive analysis on effective treatment strategies, emerging research, and multidisciplinary approaches for various neurodegenerative diseases.	Provides guidance to the interdisciplinary pain management community regarding the most effective pain strategies.	A MEDLINE-indexed, peer-reviewed journal translating recent genomic, genetic and 'omic advances into the clinical context.	Focuses on the emergence of new pharmacogenomic initiatives and their impact on R&D and regulatory strategies.
Medline indexed?	Yes	Yes	Yes	Yes	Yes	Yes







Journal	Regenerative Medicine	Bioanalysis	Future Medicinal Chemistry	Pharmaceutical Patent Analyst	Therapeutic Delivery
Impact Factor	2.4	1.9	3.2	1.8	3.0
Scope	The journal's scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization.	A MEDLINE-indexed, peer-reviewed journal covering scientific, technical and regulatory developments in bioanalysis.	A MEDLINE-indexed, journal publishing original research and critical reviews of the latest milestones in the field of medicinal chemistry.	Presents enlightened opinion and commentary on pressing IP issues related to the pharmaceutical patent life-cycle or to R&D more broadly.	Focuses on how the technological, pharmacological, clinical and physiological aspects deliver modern therapeutics to patients.
Medline indexed?	Yes	Yes	Yes	Yes	Yes

Expert Medicine Open Access Journals



Journal	Biotechniques	CNS Oncology	Colorectal Cancer	Future Neurology	Future Rare Diseases
Impact Factor	2.2	N/A	2.7	0.6	N/A
Scope	Publishing original laboratory methods, related technical and software tools, and methods-oriented review articles that are of broad interest to professional life scientists, as well as to scientists from other disciplines (e.g., chemistry, physics, computer science, plant and agricultural science and climate science) interested in life science applications for their technologies.	Provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances in clinical practice in the field are reported and analyzed by international experts, and the importance of the most recent advances in molecular biology are explained.	Research into diagnosis and optimum treatment of the disease is progressing rapidly, with new advances reported every day. Colorectal Cancer presents reviews, analysis and commentary on all aspects of colorectal cancer.	Aims to disseminate basic, translational and clinical research, focusing on the latest advances and their potential impact on the treatment of neurological diseases and disorders. Publishes a wide variety of article types including original research, reviews and opinion pieces, all of which are presented in concise, at-a-glance formats.	A fully Open Access resource for all those working in the field, including scientists, clinicians, policy makers and patient advocates, to share knowledge and provide increased exposure to the vital work being carried out in the research into rare diseases and the development of treatments.
Medline indexed?	Yes	Yes	No	No	No



Journal	Future Science OA	Hepatic Oncology	Future Endocrinology & Metabolism	Lung Cancer Management	Melanoma Management
Impact Factor	2.4	1.2	N/A	0.9	1.0
Scope	The journal covers research and discussion related to advances in biotechnology, medicine and health.	<i>Hepatic Oncology</i> publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations.	Publishing the latest research findings in the diagnosis and management of endocrine and metabolic disorders, our focus is to bridge the gap between groundbreaking research and transformative clinical applications, providing valuable insights from bench to bedside for healthcare professionals, caregivers and patients alike. Previously known as <i>International Journal of Endocrine Oncology</i>	Addresses key issues and current understanding in the diagnosis, staging and treatment of disease by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic.	A fully Open Access resource for all those working in the field, including scientists, clinicians, policy makers and patient advocates, to share knowledge and provide increased exposure to the vital work being carried out in the research into rare diseases and the development of treatments.
Medline indexed?	No	PMC indexed	No	PMC indexed	PMC indexed

Expert Research

Our Expert Research journals share the same high editorial standards as the Expert Collection. With a high-level of engagement with industry organisations such as ISMPP, COPE, EMWA, these journals offer an innovative and flexible approach to help your research make an impact.



The Expert Research series comprises:



Current Medical Research & Opinion (CMRO)

Impact Factor 2.4
CiteScore 4.4

CMRO publishes research focused on new and existing drugs and therapies, best practices in patient care, developments in diagnostic medicine and medical technology, and innovations in medical and scientific publishing.

Medline Indexed?
Yes



Journal of Medical Economics (JME)

Impact Factor 2.9
CiteScore 4.5

Journal of Medical Economics is a MEDLINE-indexed, international journal publishing rigorously peer-reviewed review articles and original papers in the pharmacoeconomics and healthcare research community.

Medline Indexed?
Yes



Postgraduate Medicine

Impact Factor 2.6
CiteScore 6.1

The journal publishes research which supports primary care physicians in solving clinical problems and improving patient care.

Medline Indexed?
Yes




Hospital Practice

CiteScore 2.8

Publishes research on in-hospital treatments and protocols to advance best practice, improve patient care, and aid physicians in solving clinical problems.

Medline Indexed?
Yes



Author Services

Accelerated Publication

For time-sensitive research, many journals offer two options for Accelerated Publication: 3-5 weeks from submission to online publication and 7-9 weeks from submission to online publication. Fees apply.

Reprints & ePrints

Clinical content published in Taylor & Francis journals can help demonstrate the benefits of your products to your customers.

Supplements

Targeted, cost-effective and high-impact reach, connecting the topical and timely knowledge from your network of key opinion leaders with our global readership.

Article Collections

The Expert Collection has an annual calendar of article collections, planned by our editors to cover the most rapidly advancing and relevant topics in medicine. Find the full list at: **think.taylorandfrancis.com/editorial-calendar-2024**

Our Ethics

All Expert Collection, Expert Medicine, and Expert Research titles are independently peer-reviewed and require full author disclosures. As a publisher, Taylor & Francis uphold the highest standards of ethical publishing and comply with ICMJE, COPE and GPP-3 guidelines.

<https://taylorandfrancis.com/partnership/commercial/publishing-services/conference-supplements/>

Enrich your publication plan with a standalone or supplementary podcast or video.

Videos can be supplied as Video Abstracts, or complementary videos at the time of submission with your paper and hosted in line with your paper on publication.

Alternatively, we can offer our standalone video journal platform, The Video Journal of Biomedicine. This is a peer-reviewed video journal providing a novel platform for authors to present their latest research or discuss their recently published peer reviewed paper in short high quality, open access video format.

All Video Journal of Biomedicine articles are:

- Standalone video articles
- Subject to double anonymised peer reviewed
- Assigned a fully citeable DOI making the video independently discoverable
- Videos can discuss any article from any journal from any publisher or be an original submission
- Can be linked to a paper on Taylor & Francis online
- Option to be filmed by Taylor & Francis or publish with our “publication only” package

Podcast articles

Podcast articles offer a novel channel to inform HCP's of new literature. Podcast articles go through the same rigorous peer-review process as normal manuscripts. These can be on any topic that fits within scope of the specified journal, ranging from KOL interviews, patient perspectives on treatments to clinical trial protocols or research.


Feel free to reach out to the Publication Solutions team for any guidance with podcast or video articles with a pre submission enquiry, (pubsols@tandf.co.uk).



Plain Language

Translating research into plain language can help authors explain their research to wider audiences, recognizing the importance of making scientific literature understandable to non-specialists. In addition to expanding article reach and increasing audience engagement, plain language can also provide the following benefits:

- Improve equal and fair access to scientific research outcomes
- Enable audiences to translate complex science into practical knowledge and initiatives
- Helps readers identify important information quickly and bookmark it for reading
- Increase the primary publication's readership and its associated metrics
- Connect with and influence important stakeholders, practitioners, and other decision-makers
- Expand professional networks, raising their profiles in the scientific and wider communities



Plain language summaries (PLS)

PLS provide a summary of the article abstract and are published following the main abstract within the article itself. PLS undergo peer review within articles.

Plain Language Summary of Publication

Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer

Gerald W Prager¹, Julien Taieb¹, Marwan Fakih¹, Fortunato Ciardiello⁴, Eric Van Cutsem⁵, Elena Elez¹, Lucjan Wyrwicz⁷, Danil Stroyakovskiy⁸, Gabor Liposits⁹, Igor Bondarenko¹⁰, Dominik P Modest¹¹, Nadia Amella¹² & Josep Taberner¹³, for the SUNLIGHT Investigators

Full affiliation information can be found at the end of this plain language summary.

First draft submitted 3 May 2024; Accepted for publication 3 June 2024

Where can I find the original article on which this summary is based?

The original article discussed in this summary, called 'Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer', was published in *The New England Journal of Medicine* in 2023. You can read the original article for free at: <https://www.nejm.org/doi/full/10.1056/NEJMoa2310983>

There is also a 'quick-take' video summarizing the findings, which is available to watch for free (after signing in with a free account) at: <https://www.nejm.org/doi/10.1056/NEJMed0702929/full>

Summary

How to say (double click sound icon to play sound).

What is this summary about?

This is a summary describing the results from a phase 3 clinical trial called SUNLIGHT. The study looked at treatment with orally administered trifluridine/tipiracil plus intravenously administered bevacizumab in people with metastatic colorectal cancer (mCRC) that is refractory to treatment.

This study included people whose cancer had grown or spread beyond its original location after no more than two previous treatments. People in the study received either the combination of trifluridine/tipiracil plus bevacizumab or they received trifluridine/tipiracil alone. The aims of the study were to see how long people lived after treatment with trifluridine/tipiracil plus bevacizumab compared with trifluridine/tipiracil alone and to find out how well the combination of trifluridine/tipiracil plus bevacizumab worked at slowing down the spread of the cancer. Researchers also looked at side effects from taking the medicines and at how treatment affected people's physical functioning.

What are the key takeaways?

People in the combination group lived longer (a median of 10.8 months) than people who received trifluridine/tipiracil alone (7.5 months). In addition, the time it took for the cancer to worsen was longer for those who received the combination treatment (a median of 5.6 months) compared with those who received trifluridine/tipiracil alone (2.4 months). People's physical functioning took longer to worsen with combination therapy (a median of 9.3 months) than it did with trifluridine/tipiracil alone (6.3 months), as measured by the impact of treatment on people's ability to carry out daily living activities. The most common side effects in both treatment groups were low levels of white blood cells, known as neutropenia (neutropenia), nausea, and low levels of healthy red blood cells (anemia).

What were the main conclusions reported by the researchers?

The results from the study suggest that treatment with oral trifluridine/tipiracil plus intravenous (IV) bevacizumab could help people with refractory mCRC live longer and maintain good physical functioning, and it could slow the worsening of their cancer.

Taylor & Francis
Taylor & Francis Group

10.1080/1476684.2024.2360500 © 2024 The Authors
Future Oncol. (pub ahead of print)
ISSN 1479-6694

Plain language summary of publication (PLSP) articles

PLSPs are visually enriched articles providing a summary of a key publication from any journal published worldwide. Published as an independent, standalone publication, PLSPs are fully citable and discoverable in their own right. More information can be found at the website www.plainlanguagesummaries.com.

There are multiple publication extender options for PLSPs, including translations in local languages, animated videos and podcasts.

Independently of publishing PLSPs, Taylor & Francis also provide a full writing service by experienced medical writers who develop a PLSP for submission to a journal.

To receive a copy of our PLSP Author Guidelines, or if you have any questions about any of our PLSP options, please contact our expert editorial team at plainlanguagesummaries@taylorandfrancis.com.

